Bafna Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Bafna Pharmaceuticals Ltd trades at ₹317, in a confirmed uptrend and 19 weeks into that stage. That is +66.6% against its own 200-day average. It sits at 100% of a 52-week range of ₹132 to ₹317. On relative strength it has no relative-strength read yet.

Today the stock is in a confirmed uptrend — week 19 of stage 2, confirmed. At ₹317 it trades +66.6% versus its 200-day average and sits at 100% of its 52-week range (₹132–₹317).

Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +140% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Bafna Pharmaceuticals Ltd trades at 96.3× P/E, at the pricey end of its own range (95th percentile). Its long-run median P/E is 36.7×, measured across 8.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 96.3× is at the pricey end of its own range (95th percentile), against a long-run median of 36.7× measured over 8.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Bafna Pharmaceuticals Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 12.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

39.8/100 — rank 34 of 44 in Pharma - Formulators · 60% evidence confidence

Bafna Pharmaceuticals Ltd scores 39.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 34. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 11.5 + 7.3 + 8.7 + 12.3 = 39.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Bafna Pharmaceuticals Ltd reported ₹26.6 Cr of revenue in the Jun 26 quarter, −23.2% year on year. Over 10 years it has compounded at 5.9% a year. The last full year, FY26, came in at ₹151 Cr. The last four reported quarters add to ₹143 Cr.

FY26 revenue came in at ₹151 Cr (+3.4% on the year), capping 10 years at 5.9% compound. The latest quarter (Jun 26) printed ₹26.6 Cr, −23.2% year on year.

Pace check: the last four quarters averaged −2.9% growth against the decade's 5.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −3.1% over the last 4 quarters against −0.4%/yr over the last 8 — stabilising; TTM profit −5.8% vs +427.5%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Bafna Pharmaceuticals Ltd's operating margin is 3.4% in the Jun 26 quarter, −11.3 percentage points against the same quarter a year ago. Across 15 fiscal years the operating margin has ranged −77.0% to 15.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 3.4%, −11.3 pp against the same quarter a year ago. Across 15 fiscal years the operating margin has ranged −77.0%–15.0%.

🚨 Why the margin moved: operating margin went −11.3 pp year on year while gross margin went +2.6 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Bafna Pharmaceuticals Ltd earned ₹0.1 Cr of net profit in the Jun 26 quarter, −97.6% year on year. Full-year FY26 profit was ₹11.0 Cr. That is 0.3% of the quarter's revenue. The same quarter a year earlier earned ₹3.4 Cr. 2 of the last 12 reported quarters were loss-making.

Jun 26 profit was ₹0.1 Cr, −97.6% year on year. On the full year, FY26 printed ₹11.0 Cr (+175.0%).

🚨 Why profit moved: revenue contributed −23.2% and the margin −11.3 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +31.3% vs revenue −2.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 209% of Bafna Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹15.0 Cr of operating cash against ₹11.0 Cr of profit. After ₹25.0 Cr of capital spending, ₹−10.0 Cr was left as free cash.

FY26: operating cash of ₹15.0 Cr against reported profit of ₹11.0 Cr, leaving free cash of ₹−10.0 Cr after ₹25.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 209% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 209%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 3.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Bafna Pharmaceuticals Ltd's cash conversion cycle runs 96 days in FY26, down from 96 days in FY21. Capital spending ran ₹59.0 Cr over the last 3 years. At FY26 sales of ₹151 Cr each day of that cycle holds about ₹0.4 Cr, so roughly ₹40.0 Cr sits inside the business at any moment.

FY26: debtors at 106 days, inventory at 129 days — roughly 4.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 96 days, tighter than FY21's 96.

The full loop: cash goes out to suppliers and production on day 0; stock waits 129 days to sell; customers pay about 106 days after that; and suppliers themselves are paid at 139 days — netting out to the 96-day cycle.

In money terms: at FY26 sales of ₹151 Cr, each day of the cycle holds about ₹0.4 Cr — so the 96-day loop keeps roughly ₹40.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹59.0 Cr over the last 3 fiscal years against ₹16.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Bafna Pharmaceuticals Ltd earns a ROCE of 12% in FY26. That is up from a trough of −35% in FY18. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 7.3% net margin on 0.86× asset turns.

FY26 ROCE is 12%, recovered from a FY18 trough of −35% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 7.3% net margin × 0.86× asset turns × 1.83× balance-sheet leverage ≈ 11.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Bafna Pharmaceuticals Ltd carries ₹37.0 Cr of borrowings against ₹96.0 Cr of equity in FY26, a debt-to-equity of 0.39. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹15.0 Cr to ₹37.0 Cr. Capital spending ran ₹59.0 Cr across the last 3 of those years.

FY26: borrowings of ₹37.0 Cr against equity of ₹96.0 Cr — a debt-to-equity of 0.39. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹15.0 Cr to ₹37.0 Cr while capital spending ran ₹59.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 13.3 points of Bafna Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 75.0% of the company. Foreign institutions moved +9.3 points over the same window, to 9.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −13.3 points over 8 quarters to 75.0%; Foreign institutions: +9.3 points over 8 quarters to 9.3%.

🚨 Why the register moved: promoters drove it (−13.3 points), absorbed on the other side by foreign institutions (+9.3 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Bafna Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions